Scopio Labs Introduces Revolutionary AI Solution for Blood Morphology Automation
In a significant advancement for laboratory diagnostics, Scopio Labs has introduced the Complete Blood Morphology (CBM®) analyzer, an innovative AI-based solution designed to fully automate blood morphology analysis. This development marks a pivotal shift in the field of hematology, enabling laboratories to analyze ten times more cells compared to current benchmarks used in blood cell morphology. The CBM® system addresses the ongoing staffing crisis in clinical laboratories, which has exacerbated inefficiencies and affected patient care.
Scopio Labs has been at the forefront of transforming cell analysis through its proprietary Full-Field imaging technology and comprehensive analytics platform. The recent unveiling of CBM® aims to close the automation gap that continues to plague hematology workflows. Traditional methods of peripheral blood smear (PBS) reviews rely heavily on human involvement, leading to increased bottlenecks and variability in results due to labor-intensive processes.
Despite the automation of Complete Blood Counts (CBCs) for many years, the necessity for manual review during PBS remains a challenge that Scopio aims to surmount with CBM®. As Itai Hayut, CEO of Scopio Labs, remarked, the vision is to establish a fully integrated and automated process in hematology, ultimately reshaping market dynamics and enhancing workflows from CBC to final results.
To reinforce its journey toward this ambitious goal, Scopio Labs has secured an additional $10 million investment from Viola Growth, elevating its total Series D funding to $52 million. This funding will expedite the deployment of CBM® in clinical laboratory settings, moving the technology from development phases to practical application.
CBM® leverages advanced computational imaging and artificial intelligence to foster a standardized, autonomous review process for blood morphology. Current hematology labs utilizing Scopio's technology report enhanced operational performance and efficiency, positioning them advantageously for the widespread adoption of CBM® in the near future.
Moreover, the implications of this breakthrough extend beyond operational enhancements. Scopio Labs envisions that the integration of automated morphology analysis will lead to the development of consistent and precise biomarkers that could revolutionize disease detection and monitoring through blood tests. By converting traditional workflows into faster, more reliable processes, CBM® promises to expedite patient access to critical diagnostics and treatment options, thereby significantly enhancing healthcare outcomes.
As part of ongoing efforts to raise awareness about this transformative technology, Scopio Labs will present the CBM® at the upcoming ADLM 2025 Annual Conference in Chicago, showcasing its capabilities to industry professionals and stakeholders. The technology is currently not available for in vitro diagnostic use yet; however, Scopio Labs holds CE mark and FDA clearance for other related digital imaging applications, including those for peripheral blood smear and bone marrow aspirate analysis.
Scopio Labs is committed to redefining the landscape of cell morphology analysis through its digital solutions, supporting laboratory teams and healthcare providers in diagnosing blood-related medical conditions with greater accuracy and speed. As the demand for streamlined and effective diagnostics continues to grow amidst staffing shortages and increasing patient needs, innovations such as CBM® are critical in modernizing healthcare and improving patient outcomes.
To learn more about Scopio Labs and its innovative products, visit their official website at www.scopiolabs.com. Scopio Labs aims to lead the charge in hematology diagnostics, empowering laboratories with cutting-edge technology that not only meets today’s challenges but also anticipates future needs.
Scopio Labs has been at the forefront of transforming cell analysis through its proprietary Full-Field imaging technology and comprehensive analytics platform. The recent unveiling of CBM® aims to close the automation gap that continues to plague hematology workflows. Traditional methods of peripheral blood smear (PBS) reviews rely heavily on human involvement, leading to increased bottlenecks and variability in results due to labor-intensive processes.
Despite the automation of Complete Blood Counts (CBCs) for many years, the necessity for manual review during PBS remains a challenge that Scopio aims to surmount with CBM®. As Itai Hayut, CEO of Scopio Labs, remarked, the vision is to establish a fully integrated and automated process in hematology, ultimately reshaping market dynamics and enhancing workflows from CBC to final results.
To reinforce its journey toward this ambitious goal, Scopio Labs has secured an additional $10 million investment from Viola Growth, elevating its total Series D funding to $52 million. This funding will expedite the deployment of CBM® in clinical laboratory settings, moving the technology from development phases to practical application.
CBM® leverages advanced computational imaging and artificial intelligence to foster a standardized, autonomous review process for blood morphology. Current hematology labs utilizing Scopio's technology report enhanced operational performance and efficiency, positioning them advantageously for the widespread adoption of CBM® in the near future.
Moreover, the implications of this breakthrough extend beyond operational enhancements. Scopio Labs envisions that the integration of automated morphology analysis will lead to the development of consistent and precise biomarkers that could revolutionize disease detection and monitoring through blood tests. By converting traditional workflows into faster, more reliable processes, CBM® promises to expedite patient access to critical diagnostics and treatment options, thereby significantly enhancing healthcare outcomes.
As part of ongoing efforts to raise awareness about this transformative technology, Scopio Labs will present the CBM® at the upcoming ADLM 2025 Annual Conference in Chicago, showcasing its capabilities to industry professionals and stakeholders. The technology is currently not available for in vitro diagnostic use yet; however, Scopio Labs holds CE mark and FDA clearance for other related digital imaging applications, including those for peripheral blood smear and bone marrow aspirate analysis.
Scopio Labs is committed to redefining the landscape of cell morphology analysis through its digital solutions, supporting laboratory teams and healthcare providers in diagnosing blood-related medical conditions with greater accuracy and speed. As the demand for streamlined and effective diagnostics continues to grow amidst staffing shortages and increasing patient needs, innovations such as CBM® are critical in modernizing healthcare and improving patient outcomes.
To learn more about Scopio Labs and its innovative products, visit their official website at www.scopiolabs.com. Scopio Labs aims to lead the charge in hematology diagnostics, empowering laboratories with cutting-edge technology that not only meets today’s challenges but also anticipates future needs.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.